Continuing bevacizumab beyond progression of platinum-sensitive ovarian cancer

A phase 3 study at 82 sites in four countries found that continuing bevacizumab beyond progression combined with chemotherapy for platinum-sensitive recurrent ovarian cancer improved progression-free survival compared with standard chemotherapy alone.